

Unless otherwise defined herein, capitalised terms in this announcement shall have the same meanings as those defined in the prospectus dated Wednesday, June 24, 2020 (the “**Prospectus**”) issued by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (the “**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company, the Hong Kong Public Offering and the International Offering described below before deciding whether or not to invest in the H Shares thereby offered.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The H Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”), or any state securities laws of the United States.

The Offer Shares may not be offered, sold, pledged or transferred within the United States, except pursuant to an effective registration statement or in accordance with an available exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of securities of the Company in the United States.

In connection with the Global Offering, Goldman Sachs (Asia) L.L.C., as the stabilization manager (the “**Stabilization Manager**”) or its affiliates or any person acting for it on behalf of the Underwriters, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the H Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilization Manager or its affiliates or any person acting for it to conduct any such stabilizing action, which, if taken, will be done at the sole and absolute discretion of the Stabilization Manager or its affiliates or any person acting for it and in what the Stabilization Manager reasonably regards as the best interest of the Company, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilization action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing actions cannot be taken to support the price of the H Shares for longer than the stabilization period which begins on the Listing Date, and is expected to expire on Thursday, July 30, 2020, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, demand for the H Shares, and therefore the price of the H Shares, could fall.



**Hepalink**

**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**

**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

## **Global Offering**

<b>Number of Offer Shares under the Global Offering</b>	220,094,500 H Shares (subject to the Over-allotment Option)
<b>Number of Hong Kong Offer Shares</b>	22,010,000 H Shares (subject to adjustment)
<b>Number of International Offer Shares</b>	198,084,500 H Shares (subject to adjustment and the Over-allotment Option)
<b>Minimum Offer Price</b>	HK\$20.60 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)
<b>Nominal value</b>	RMB1.00 per H Share
<b>Stock code</b>	9989

*Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers  
(in alphabetical order)*

**Goldman  
Sachs**

**or anST u ley**

An application has been made by the Company to the Listing Committee of the Stock Exchange for the listing of, and permission to deal in, the H Shares to be issued pursuant to the Global Offering (including any additional H Shares which may be issued pursuant to the exercise of the Over-allotment Option). Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Wednesday, July 8, 2020, dealing in the H Shares on the Main Board are expected to commence at 9:00 a.m. on Wednesday, July 8, 2020.

The Global Offering comprises the Hong Kong Public Offering of initially 22,010,000 H Shares (subject to adjustment), and the International Offering of initially 198,084,500 H Shares (subject to adjustment and the Over-allotment Option). The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the section headed “Structure of the Global Offering” in the Prospectus. In accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to Practice Note 18 of the Listing Rules, the maximum total number of Offer Shares that may be reallocated to the Hong Kong Public Offering following such reallocation shall be not more than double the initial allocation to the Hong Kong Public Offering (i.e. 44,020,000 H Shares), and the final Offer Price shall be fixed at the low-end of the indicative Offer Price range (i.e., HK\$18.40 per H Share) stated in the Prospectus.

In connection with the Global Offering and pursuant to the International Underwriting Agreement, the Company is expected to grant the Over-Allotment Option to the International Underwriters, exercisable by the Joint Global Coordinators (on behalf of the International Underwriters) at any time from the Listing Date until 30 days after the last day for lodging applications under the Hong Kong Public Offering, pursuant to which the Company may be required to issue up to an aggregate of 33,014,000 additional H Shares, representing not more than 15% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price to cover over-allocations (if any) in the International Offering. In the event the Over-allotment Option is exercised, an announcement will be made by the Company on the Company’s website at [www.hepalink.com](http://www.hepalink.com) and the website of the Stock Exchange at [www.hke.m.s.hk](http://www.hke.m.s.hk).

Subject to the granting of listing of, and permission to deal in, the H Shares on the Stock Exchange and compliance with the stock admission requirements of HKSCC, the H Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the Listing Date or such other date as determined by HKSCC. Settlement of transactions between participants of the Stock Exchange is required to take place in CCASS on the second Business Day



**CMB International Capital Limited**

45/F Champion Tower  
3 Garden Road  
Central  
Hong Kong

**Haitong International Securities Company<sup>2</sup> Limited**

22/F Li Po Chun Chambers  
189 Des Voeux Road Central  
Hong Kong

**BOCI Asia Limited**

26th Floor  
Bank of China Tower  
1 Garden Road  
Hong Kong

**CLSA Limited**

18/F, One Pacific Place  
88 Queensway  
Hong Kong

**ICBC International Capital Limited**

37/F ICBC Tower  
3 Garden Road  
Central  
Hong Kong

**SPDB International Capital Limited**

33/F, SPD Bank Tower  
One Hennessy  
1 Hennessy Road  
Hong Kong

2. any of the following branches of the receiving bank of the Hong Kong Public Offering:

**Bank of China (Hong Kong) Limited**

<b>District</b>	<b>Branch Name</b>	<b>Address</b>
Hong Kong Island	Bank of China Tower Branch	1 Garden Road, Hong Kong
Kowloon	Kwun Tong Plaza Branch	G1 Kwun Tong Plaza, 68 Hoi Yuen Road, Kwun Tong, Kowloon
	Yau Ma Tei Branch	471 Nathan Road, Yau Ma Tei, Kowloon
New Territories	Metro City Branch	Shop 209, Level 2, Metro City Phase 1, Tseung Kwan O, New Territories
	Yuen Long Branch	102–108 Castle Peak Road, Yuen Long, New Territories
	Castle Peak Road (Tsuen Wan) Branch	G/F–1/F, Sin Ching Building 201–207 Castle Peak Road (Tsuen Wan), Tsuen Wan, New Territories

Copies of the Prospectus, together with the **YELLOW** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Wednesday, June 24, 2020 until 12:00 noon on Tuesday, June 30, 2020 from the Depository Counter of HKSCC at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong or from your stockbroker, who may have such Application Forms and the Prospectus available.

The **WHITE** or **YELLOW** Application Form completed in accordance with the instructions printed thereon, together with a check or a banker's cashier order payable to “**BANK OF CHINA (HONG KONG) NOMINEES LIMITED SHENZHEN HEPALINK PHARMACEUTICAL PUBLIC OFFER**” attached should be deposited in the special collection boxes provided at any of the branches of the receiving bank referred to above on such dates and during such time as specified in the Application Forms.

Your **WHITE** or **YELLOW** Application Forms can be lodged at the following times on the following dates:

Wednesday, June 24, 2020	— 9:00 a.m. to 5:00 p.m.
Friday, June 26, 2020	— 9:00 a.m. to 5:00 p.m.
Saturday, June 27, 2020	— 9:00 a.m. to 1:00 p.m.
Monday, June 29, 2020	— 9:00 a.m. to 5:00 p.m.
Tuesday, June 30, 2020	— 9:00 a.m. to 12:00 noon

The latest time for lodging your application is 12:00 noon on Tuesday, June 30, 2020. The application lists will be open from 11:45 a.m. to 12:00 noon on that day, subject only to the weather conditions, as described in the section headed “How to Apply for Hong Kong Offer Shares — 10. Effect of Bad Weather and/or Extreme Conditions on the Opening of the Application Lists” in the Prospectus.

Applicants applying by the **HK eIPO White Form** service may submit applications through the **IPO App** or the designated website at [www.hkeipo.hk](http://www.hkeipo.hk) from 9:00 a.m. on Wednesday, June 24, 2020 until 11:30 a.m. on Tuesday, June 30, 2020 (24 hours daily, except on the last application date) and the latest time for completing full payment of application monies in respect of such applications will be 12:00 noon on Tuesday, June 30, 2020 or such later time as described in the section headed “How to Apply for the Hong Kong Offer Shares — 10. Effect of Bad Weather and/or Extreme Conditions on the Opening of the Application Lists” in the Prospectus.

CCASS Clearing/Custodian Participants can input **electronic application instructions** at the following times on the following dates:<sup>(1)</sup>

Wednesday, June 24, 2020	— 9:00 a.m. to 8:30 p.m.
Friday, June 26, 2020	— 8:00 a.m. to 8:30 p.m.
Monday, June 29, 2020	— 8:00 a.m. to 8:30 p.m.
Tuesday, June 30, 2020	— 8:00 a.m. to 12:00 noon

*Note:*

- (1) The times are subject to change as HKSCC may determine from time to time with prior notification to CCASS Clearing/Custodian Participants and/or CCASS Investor Participant.

CCASS Investor Participants can input **electronic application instructions** from 9:00 a.m. on Wednesday, June 24, 2020 until 12:00 noon on Tuesday, June 30, 2020 (24 hours daily, except on Tuesday, 30 June 2020, the last application day).

Please refer to the sections headed “Structure of the Global Offering” and “How to Apply for the Hong Kong Offer Shares” in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

The Company expects to announce the final Offer Price, the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares (i) on the website of the Stock Exchange [www.hkeipo.hk](http://www.hkeipo.hk); and (ii) on the Company’s website [www.hepalink.com](http://www.hepalink.com) on Tuesday, July 7, 2020. The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants under the Hong Kong Public Offering will be available at the times and date and in the manner specified in the section headed “How to Apply for the Hong Kong Offer Shares — 11. Publication of Results” in the Prospectus.

No temporary documents of title will be issued in respect of the H Shares. No receipt will be issued for sums paid on application. H Share certificates will only become valid at 8:00 a.m. on Wednesday, July 8, 2020 provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting” in the Prospectus has not been exercised. Dealings in the H Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Wednesday, July 8, 2020. The H Shares will be traded in board lots of 500 H Shares each. The stock code of the H Shares is 9989.

On behalf of the Board of Directors  
**Shen hen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li LI**  
*Chairman*

Hong Kong, Wednesday, June 24, 2020

*As at the date of this announcement, the board of directors of the Company comprises Mr. Li Li, Ms. Li Tan, Mr. Shan Yu, Mr. Sun Xuan and Mr. Bu Haihua as executive Directors; and Dr. Lu ua a Lair. iaHaihir. ( )0.5 (a)0.5 (n)0.5 (,)0.5 ( )0.5 (2)0.*